<DOC>
	<DOC>NCT02559973</DOC>
	<brief_summary>This is a single-center, randomized, open-label, single-dose, parallel-group study which will enroll and randomize approximately 48 subjects (to achieve 36 completers) with opioid use disorder (OUD) who are seeking treatment for OUD. The study includes both a Residential (Inpatient) and Non-Residential (Outpatient) Period.</brief_summary>
	<brief_title>Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Currently meets DSM5 criteria for moderate or severe opioid use disorder (OUD) Is seeking treatment for OUD Body mass index: ≥ 18.0 to ≤ 35.0 kg/m^2 Females: Female individuals of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have a negative serum pregnancy test prior to enrollment and must agree to use a medically acceptable means of contraception from Screening through at least 6 months after the last dose of Investigational Medicinal Product (IMP). Males: Male individuals with female partners of childbearing potential must agree to use medically acceptable contraception after signing the informed consent form through at least 6 months after the last dose of IMP. Male individuals must also agree not to donate sperm during the study and for 6 months after receiving the last dose of IMP. Have a normal electrocardiogram (ECG) or ECG with no clinically significant findings in the opinion of the Investigator or medically qualified subinvestigator at Screening and through predose on Day 1. Agree not to take any buprenorphinecontaining products, other than those administered for the current study, throughout the duration of the study. Willing to adhere to study procedures and provide written informed consent prior to start of any study procedures. Current diagnosis, other than OUD, requiring chronic opioid treatment. Pregnant or lactating females. Have an ECG demonstrating a corrected QT interval using Fridericia's calculation (QTcF) &gt; 450 msec in males and QTcF &gt; 470 msec in females upon admission to the residential facility or prior to administration of RBP6000. Currently meet the criteria for diagnosis of moderate or severe substance use disorder, by DSM5 criteria, for any substances other than opioids, and/or tobacco. Had a significant traumatic injury, major surgery, or open biopsy within the 4 weeks prior to signing the informed consent form. Used buprenorphinecontaining products within the 14 days prior to signing the informed consent form. Have a history of suicidal ideation within the 30 days prior to signing the informed consent form or prior to study drug administration Have a history or presence of allergic or adverse response (including rash or anaphylaxis) to buprenorphine, naloxone, methadone, or the ATRIGEL Delivery System. Individuals who have a positive urine drug screen (UDS) prior to admission to the residential facility for barbiturates, benzodiazepines, buprenorphine, or methadone.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>opioid use disorder</keyword>
</DOC>